FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
Botensilimab and balstilimab combinations deliver unprecedented tumor responses across multiple cancer types, fueling optimism for harder-to-treat colorectal, breast, …
In a world-first, an infant with a fatal genetic disorder receives a custom, in vivo CRISPR therapy, showcasing …
Breakthroughs in personalized therapies and AI-driven tools are reshaping how cancer is diagnosed and treated, promising better outcomes …
First new targeted therapy in more than a decade offers relief to patients with hives uncontrolled by antihistamines
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
The European regulatory body’s February 2025 meeting brings fresh treatment options for immunodeficiency and autoimmunity among other conditions, …
The FDA has approved Merilog (insulin-aspart-szjj), marking the first biosimilar to Novolog (insulin aspart), and widening affordable insulin …
With increasing geopolitical disruptions and shifting trial strategies, India emerges as an attractive destination for early-stage clinical trials, …
Already a subscriber? Log in